MRNA
NASDAQModerna
$138.89
-6.24 (-4.30%)
2026-08-24 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$21.75B
P/E Ratio
N/A
52W Low
52W High
$22.28
$176.66
Volume
31.5M
Analyst Rating
Hold
Target: $45
10 Analyst Ratings
Strong Buy
0
Buy
0
Hold
10
Sell
0
Price Target Range
Low: $43
Avg: $45
High: $49
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseas...
Employees
4,700
Website
modernatx.com
Latest News
The Motley Fool - 5d ago
Why Moderna Stock Skyrocketed Today
The Motley Fool - 5d ago
Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Here's What That Means for Investors.
The Motley Fool - 28d ago
After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy?
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | $1.94B | -158.1% | -$2.82B | -$1.68B |
| 2024 | $3.20B | -123.3% | -$3.56B | -$1.95B |
| 2023 | $6.85B | -61.9% | -$4.71B | -$2.41B |
| 2022 | $18.88B | 49.9% | $8.36B | $5.38B |
| 2021 | $17.74B | 75.0% | $12.20B | $13.90B |
| 2026 Q2 | $145.0M | -562.1% | -$782.0M | -$489.0M |
| 2026 Q1 | $389.0M | -356.8% | -$1.34B | -$568.0M |
| 2025 Q4 | $678.0M | -126.4% | -$826.0M | $990.0M |
| 2025 Q3 | $1.02B | -25.6% | -$200.0M | -$814.0M |
| 2025 Q2 | $142.0M | -638.7% | -$825.0M | -$916.0M |
| 2025 Q1 | $107.0M | -981.3% | -$971.0M | -$910.0M |
| 2024 Q4 | $956.0M | -130.3% | -$1.12B | $1.35B |
| 2024 Q3 | $1.85B | -3.8% | $13.0M | -$1.42B |